[go: up one dir, main page]

AR093391A1 - POLIPEPTIDOS DERIVADOS DEL TGFb Y SUS USOS - Google Patents

POLIPEPTIDOS DERIVADOS DEL TGFb Y SUS USOS

Info

Publication number
AR093391A1
AR093391A1 ARP130104078A ARP130104078A AR093391A1 AR 093391 A1 AR093391 A1 AR 093391A1 AR P130104078 A ARP130104078 A AR P130104078A AR P130104078 A ARP130104078 A AR P130104078A AR 093391 A1 AR093391 A1 AR 093391A1
Authority
AR
Argentina
Prior art keywords
tgfb
polypeptides
alk5
pharmaceutical compositions
fusion proteins
Prior art date
Application number
ARP130104078A
Other languages
English (en)
Inventor
Carmenate Portilla Tania
De Jesus Corria Osorio Angel
Leon Monzon Kalet
Pupo Merio Amaury
Perez Rodriguez Saumel
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49765213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR093391(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Publication of AR093391A1 publication Critical patent/AR093391A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Polipéptidos mutados de la molécula TGFb (factor transformante del crecimiento b) cuya secuencia primaria tiene una alta homología con la secuencia del TGFb humano. Estas muteínas pierden la capacidad de interacción con ALK5 pero conservan la interacción con el resto de los receptores que forman parte del complejo receptor (TbRII y TbRIII). Tienen la propiedad de antagonizar la señalización del todas las variantes naturales de los ligandos TGFb, dependiente del reclutamiento de ALK5 en el complejo receptor y tienen un efecto inmunomodulador. Composiciones farmacéuticas que comprenden como principio activo los polipéptidos o proteínas de fusión divulgados y con el uso terapéutico de los polipéptidos, proteínas de fusión y composiciones farmacéuticas divulgados dado su efecto modulador del sistema inmune sobre patologías como el cáncer, enfermedades que cursan con fibrosis y en enfermedades infecciosas crónicas.
ARP130104078A 2012-11-09 2013-11-07 POLIPEPTIDOS DERIVADOS DEL TGFb Y SUS USOS AR093391A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20120158A CU24181B1 (es) 2012-11-09 2012-11-09 POLIPÉPTIDOS DERIVADOS DEL TGFß

Publications (1)

Publication Number Publication Date
AR093391A1 true AR093391A1 (es) 2015-06-03

Family

ID=49765213

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104078A AR093391A1 (es) 2012-11-09 2013-11-07 POLIPEPTIDOS DERIVADOS DEL TGFb Y SUS USOS

Country Status (28)

Country Link
US (1) US9701730B2 (es)
EP (1) EP2918284B1 (es)
JP (2) JP6298823B2 (es)
KR (1) KR102093494B1 (es)
CN (1) CN104902916B (es)
AR (1) AR093391A1 (es)
AU (1) AU2013344022B2 (es)
BR (1) BR112015010145B1 (es)
CA (1) CA2887455C (es)
CL (1) CL2015001252A1 (es)
CO (1) CO7400865A2 (es)
CU (1) CU24181B1 (es)
EA (1) EA031990B1 (es)
ES (1) ES2857176T3 (es)
HK (1) HK1213781A1 (es)
IL (1) IL238621B (es)
JO (1) JO3502B1 (es)
MX (1) MX366060B (es)
MY (1) MY173078A (es)
NZ (1) NZ707850A (es)
PE (1) PE20150890A1 (es)
PH (1) PH12015500807A1 (es)
SG (1) SG11201502980VA (es)
TN (1) TN2015000129A1 (es)
TW (1) TWI615404B (es)
UA (1) UA115678C2 (es)
WO (1) WO2014071894A1 (es)
ZA (1) ZA201504462B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3541409T (pt) * 2016-11-18 2025-02-13 Nat Res Council Canada Monómeros modificados de ftc beta e a sua utilização para inibição da sinalização de ftc beta
PL238850B1 (pl) * 2017-10-19 2021-10-11 Calther Polska Spolka Z Ograniczona Odpowiedzialnoscia Aktywna forma transformującego czynnika wzrostu beta 1 (TGFβ1) do zastosowania w leczeniu pacjentów z glejakami wielopostaciowymi, w przypadku których to glejaków ponad 5% komórek nowotworowych jest EGFRvIII-pozytywna

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4572899A (en) * 1998-06-16 2000-01-05 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
EP1115866A1 (en) * 1998-09-22 2001-07-18 University of Maryland at Baltimore Cystine knot growth factor mutants
US6677432B1 (en) * 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
JP2008509888A (ja) * 2004-06-30 2008-04-03 モレキュラー ロジックス，インコーポレイテッド 上皮成長因子受容体アンタゴニストおよび使用方法
US7795389B2 (en) * 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
US7557181B2 (en) * 2005-01-11 2009-07-07 Molecular Logix, Inc. Pan-HER antagonists and methods of use
GB0724051D0 (en) * 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
CN102958531A (zh) * 2010-04-22 2013-03-06 耶路撒冷希伯来大学伊森姆研究发展公司 高亲和力瘦蛋白和瘦蛋白拮抗剂

Also Published As

Publication number Publication date
CN104902916A (zh) 2015-09-09
BR112015010145A2 (es) 2017-08-22
TW201431875A (zh) 2014-08-16
WO2014071894A1 (es) 2014-05-15
CA2887455C (en) 2022-05-17
UA115678C2 (uk) 2017-12-11
EP2918284B1 (en) 2021-02-17
AU2013344022A1 (en) 2015-05-28
KR20150083848A (ko) 2015-07-20
MX366060B (es) 2019-06-26
SG11201502980VA (en) 2015-06-29
JO3502B1 (ar) 2020-07-05
PE20150890A1 (es) 2015-06-10
US20150284441A1 (en) 2015-10-08
CL2015001252A1 (es) 2015-07-17
MY173078A (en) 2019-12-25
HK1213781A1 (zh) 2016-07-15
ES2857176T3 (es) 2021-09-28
JP2015535000A (ja) 2015-12-07
EA201590914A1 (ru) 2015-09-30
CA2887455A1 (en) 2014-05-15
CU20120158A7 (es) 2014-06-27
US9701730B2 (en) 2017-07-11
EA031990B1 (ru) 2019-03-29
BR112015010145B1 (pt) 2022-06-07
ZA201504462B (en) 2018-11-28
JP6298823B2 (ja) 2018-03-20
CN104902916B (zh) 2018-04-13
JP6608473B2 (ja) 2019-11-20
IL238621B (en) 2019-12-31
JP2018111703A (ja) 2018-07-19
TWI615404B (zh) 2018-02-21
CO7400865A2 (es) 2015-09-30
EP2918284A1 (en) 2015-09-16
CU24181B1 (es) 2016-04-25
IL238621A0 (en) 2015-06-30
TN2015000129A1 (en) 2016-10-03
KR102093494B1 (ko) 2020-03-26
NZ707850A (en) 2019-08-30
MX2015005875A (es) 2015-09-10
PH12015500807A1 (en) 2015-06-08
AU2013344022B2 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
ECSP12011803A (es) Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
MX2019006733A (es) Activacion farmaceutica de una senda de señalizacion de di-nucleotido ciclico de mamifero.
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
CY1122483T1 (el) Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
BR112016026291A2 (pt) Derivados do ácido borônico e usos terapêuticos dos mesmos
CU23923B1 (es) Polipéptidos derivados de la il-2 con actividad agonista
BR112016029848A2 (pt) proteínas de fusão mic-1 e utilizações das mesmas
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
BR112017001940A2 (pt) proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso
LT2986304T (lt) Farmacinė kompozicija, gydymo būdai ir jų panaudojimas
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA202090547A3 (ru) Макроциклические деаза-оксипурины для лечения вирусных инфекций
UY36021A (es) Proteìnas fc multimèricas
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
ES2850277R1 (es) Composiciones de administración farmacéutica y usos de las mismas
AR095527A1 (es) Formulaciones de polipéptido fc-factor ix
IT201800001301A1 (it) Formulazioni in gel per la somministrazione orale di farmaci, in particolare nei pazienti disfagici
EP3643784A4 (en) RECOMBINANT HUMAN BASIC FIBROBLASTIC GROWTH FACTOR (RH-BFGF) AND PHARMACEUTICAL COMPOSITION INCLUDING RH-BFGF
EP4023227A4 (en) PHARMACEUTICAL COMPOSITION AND ITS APPLICATION
BR112016013577A2 (pt) Proteínas de fusão, seu uso e composição farmacêutica
UA114298C2 (uk) Пептид торк та вакцина, що його містить
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
BR112015022730A2 (pt) formulações de rfviii, método para conjugação covalente de rfviii com um polímero biocompatível e uso de rfviii no preparo de formulação de rfviii para tratamento de hemofilia a

Legal Events

Date Code Title Description
FG Grant, registration